Last reviewed · How we verify
Ticagrelor Tablets
At a glance
| Generic name | Ticagrelor Tablets |
|---|---|
| Sponsor | Advenchen Laboratories Nanjing Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination. (PHASE1)
- Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers (PHASE1)
- Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention (PHASE4)
- DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury (PHASE2, PHASE3)
- The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin (PHASE4)
- Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA (PHASE3)
- Brilinta Clinical Experience Investigation
- A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor Tablets CI brief — competitive landscape report
- Ticagrelor Tablets updates RSS · CI watch RSS
- Advenchen Laboratories Nanjing Ltd. portfolio CI